Granuloma Annulare (Investigational Adjunct)
Highly investigational adjunct for localized granuloma annulare; no RCT evidence; many lesions resolve spontaneously within 1-2 years.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for granuloma annulare. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- What evidence exists?
- Tier C (investigational). Anecdotal central European and Russian case reports only. Evidence-based first-line management of localized granuloma annulare is observation (about 50 percent resolve spontaneously within 2 years), high-potency topical corticosteroid, intralesional triamcinolone, or topical tacrolimus; disseminated disease may require phototherapy or systemic therapy.
- Main risks
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Who should not consider this
- Patients with disseminated or rapidly enlarging lesions (need systemic workup, including evaluation for diabetes or hyperlipidemia)
- Patients without a confirmed diagnosis — atypical lesions need biopsy to exclude granulomatous mycosis fungoides or sarcoidosis
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- Patients who are pregnant or breastfeeding (relative contraindication; insufficient safety data)
- What to ask your clinician
- Has my diagnosis been confirmed by biopsy and atypical mimics excluded?
- Have I tried topical or intralesional corticosteroid?
- Could spontaneous resolution falsely make any intervention appear effective?
- Have I been evaluated for diabetes mellitus or dyslipidemia (associations with disseminated GA)?
- What is the published evidence base for leeches in GA?
- What scarring should I expect compared to lesions that resolve spontaneously?
- When to seek urgent care
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Rapid spread, ulceration, or new systemic symptoms (could indicate a different granulomatous disease)
What this does NOT mean
- It does not mean leech therapy is FDA-cleared for granuloma annulare — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace standard topical or intralesional corticosteroid for symptomatic GA.
- It does not differentiate GA from mimics — atypical lesions still need biopsy.
- It does not address systemic associations such as diabetes or dyslipidemia.
- It does not have controlled-trial evidence, and about half of cases resolve on their own within two years anyway.
Safety cross-references
Clinical Profile
- Category
- dermatological
- ICD-10
- L92.0
- Safety tier
- low
Evidence Summary
Granuloma annulare (GA) is a benign self-limited dermal granulomatous disorder of uncertain etiology; localized GA resolves spontaneously in roughly 50 percent of cases within two years. Standard interventions when treatment is desired include high-potency topical corticosteroid, intralesional triamcinolone, cryotherapy, and topical tacrolimus; disseminated GA may require systemic therapy. No controlled clinical trial of leech therapy for granuloma annulare has been published; its use is investigational and mechanistic only. Given the high rate of spontaneous resolution, any uncontrolled observation is likely to overstate effect. Evidence is grade D.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Wollina U (2008)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Disseminated GA (systemic workup and therapy indicated)
- Possible underlying diabetes mellitus or dyslipidemia (evaluate first)
- Atypical or rapidly enlarging lesion (biopsy first to exclude granulomatous mycosis fungoides)
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.